CD33-directed Antibody Interactions

CD33-directed Immunoconjugate

Leukemia, Myeloid, Acute

Leukemia, Myelomonocytic, Acute

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-8"></a><p></p><h1>11. DESCRIPTION</h1><p class="First"><img alt="Chemical Structure" src="mylotarg-01.jpg"/></p><p>Gemtuzumab ozogamicin is an antibody-drug conjugate (ADC) composed of the CD33-directed monoclonal antibody (hP67.6; recombinant humanized immunoglobulin [Ig] G4, kappa antibody produced by mammalian cell culture in NS0 cells) that is covalently linked to the cytotoxic agent N-acetyl gamma calicheamicin. Gemtuzumab ozogamicin consists of conjugated and unconjugated gemtuzumab. The conjugated molecules differ in the number of activated calicheamicin derivative moieties attached to gemtuzumab. The number of conjugated calicheamicin derivatives per gemtuzumab molecule ranges from predominantly zero to 6, with an average of 2 to 3 moles of calicheamicin derivative per mole of gemtuzumab.</p><p>MYLOTARG (gemtuzumab ozogamicin) for injection is supplied as a sterile, white to off-white, preservative-free lyophilized cake or powder for intravenous administration. Each single-dose vial delivers 4.5 mg gemtuzumab ozogamicin. Inactive ingredients are dextran 40 (41.0 mg), sodium chloride (26.1 mg), sodium phosphate dibasic anhydrous (2.7 mg), sodium phosphate monobasic monohydrate (0.45 mg), and sucrose (69.8 mg). After reconstitution with 5 mL of Sterile Water for Injection USP, the concentration is 1 mg/mL of gemtuzumab ozogamicin with a deliverable volume of 4.5 mL (4.5 mg).</p></section>

Mylotarg

gemtuzumab ozogamicin

gemtuzumab ozogamicin 4.5 MG Injection

gemtuzumab ozogamicin 4.5 MG Injection [Mylotarg]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Submit MSL Request 

Pharmacy List 

How To Order Mylotarg 

Coverage Authorization Request 

Coverage Authorization Appeal

Letter of Medical Necessity 

Formulary Exception Letter 

Other HCP Resources: Access 

Reimbursement Information 

Billing And Coding Guide: Hospital Outpatient

Billing And Coding Guide: Physician's Office

Pfizer Oncology Together Form 

Pfizer Oncology Together Form - Spanish 

Enroll in Patient Savings Program 

Pfizer Patient Assistance Program 

Free 90-day Supply: For Uninsured Patients While Applying for Medicaid

Pfizer Oncology Patient Access Guide 

Pfizer Oncology Patient Access Guide - Spanish 

Instructions For Use: Adult AML (Combination Regimen)

Instructions For Use: Pediatric AML (Combination Regimen)

Instructions For Use: Adult AML (Single-Agent Regimen)

Instructions For Use: Relapsed or Refractory AML (Single-Agent Regimen)

Other HCP Resources 